NetworkNewsBreaks – Endonovo Therapeutics Inc.
Post# of 416
Endonovo Therapeutics (OTCQB: ENDV) is a commercial-stage developer of noninvasive Electroceutical(TM) Therapeutic devices that target patient pain and inflammation while supporting wound recovery. An article discussing the company reads, “Targeting inflammatory conditions in vital organs and peripheral tissues, Endonovo’s SofPulse(R) is clinically proven to significantly speed the recovery process and reduce the need for potentially addictive pain medications, thereby improving the patient’s natural recovery experience (http://nnw.fm/O9UUp). . . . The efficacy of SofPulse targeted pulsed electromagnetic field therapy (tPEMF), which uses targeted microcurrents to transmit gentle pulses to the tissue, is well documented and supported by peer-reviewed clinical research. Among the clinical findings for patients using tPEMF are decreases in post-surgery pain, a 2.2-fold reduction in the use of narcotics, vastly improved chronic wound healing and significant reductions in inflammation and edema (http://nnw.fm/Ys5NT).”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer